116 related articles for article (PubMed ID: 24295064)
1. 5-HT(1A) receptor: an old target as a new attractive tool in drug discovery from central nervous system to cancer.
Fiorino F; Severino B; Magli E; Ciano A; Caliendo G; Santagada V; Frecentese F; Perissutti E
J Med Chem; 2014 Jun; 57(11):4407-26. PubMed ID: 24295064
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of 5-HT1A receptors: a patent review.
Lacivita E; Di Pilato P; De Giorgio P; Colabufo NA; Berardi F; Perrone R; Leopoldo M
Expert Opin Ther Pat; 2012 Aug; 22(8):887-902. PubMed ID: 22788968
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation, and docking studies of tetrahydrofuran- cyclopentanone- and cyclopentanol-based ligands acting at adrenergic α₁- and serotonine 5-HT1A receptors.
Prandi A; Franchini S; Manasieva LI; Fossa P; Cichero E; Marucci G; Buccioni M; Cilia A; Pirona L; Brasili L
J Med Chem; 2012 Jan; 55(1):23-36. PubMed ID: 22145629
[TBL] [Abstract][Full Text] [Related]
5. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
[TBL] [Abstract][Full Text] [Related]
6. Mapping of CBV changes in 5-HT(1A) terminal fields by functional MRI in the mouse brain.
Mueggler T; Razoux F; Russig H; Buehler A; Franklin TB; Baltes C; Mansuy IM; Rudin M
Eur Neuropsychopharmacol; 2011 Apr; 21(4):344-53. PubMed ID: 20656461
[TBL] [Abstract][Full Text] [Related]
7. 1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: structure-affinity/activity relationship at alpha1-adrenoceptor subtypes and at 5-HT1A receptors.
Franchini S; Prandi A; Baraldi A; Sorbi C; Tait A; Buccioni M; Marucci G; Cilia A; Pirona L; Fossa P; Cichero E; Brasili L
Eur J Med Chem; 2010 Sep; 45(9):3740-51. PubMed ID: 20605276
[TBL] [Abstract][Full Text] [Related]
8. Receptor-genes cross-talk: effect of chronic 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin treatment on the expression of key genes in brain serotonin system and on behavior.
Popova NK; Naumenko VS; Cybko AS; Bazovkina DV
Neuroscience; 2010 Aug; 169(1):229-35. PubMed ID: 20423722
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling of the 3D structure of 5-HT(1A)R: discovery of novel 5-HT(1A)R agonists via dynamic pharmacophore-based virtual screening.
Xu L; Zhou S; Yu K; Gao B; Jiang H; Zhen X; Fu W
J Chem Inf Model; 2013 Dec; 53(12):3202-11. PubMed ID: 24245825
[TBL] [Abstract][Full Text] [Related]
10. In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue.
Hendry N; Christie I; Rabiner EA; Laruelle M; Watson J
Nucl Med Biol; 2011 Feb; 38(2):273-7. PubMed ID: 21315283
[TBL] [Abstract][Full Text] [Related]
11. [Effect of agonist and antagonist of 5-HT(1A) receptors on learning in female rats during ovarian cycle].
Fedotova IuO; Ordian NE
Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(4):493-9. PubMed ID: 20873139
[TBL] [Abstract][Full Text] [Related]
12. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
de Boer SF; Koolhaas JM
Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
[TBL] [Abstract][Full Text] [Related]
13. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress.
Yamaguchi T; Tsujimatsu A; Kumamoto H; Izumi T; Ohmura Y; Yoshida T; Yoshioka M
J Ethnopharmacol; 2012 Sep; 143(2):533-9. PubMed ID: 22819689
[TBL] [Abstract][Full Text] [Related]
14. The 5-HT(1) receptors inhibiting the rat vasodepressor sensory CGRPergic outflow: further involvement of 5-HT(1F), but not 5-HT(1A) or 5-HT(1D), subtypes.
González-Hernández A; Manrique-Maldonado G; Lozano-Cuenca J; Muñoz-Islas E; Centurión D; Maassen VanDenBrink A; Villalón CM
Eur J Pharmacol; 2011 Jun; 659(2-3):233-43. PubMed ID: 21473863
[TBL] [Abstract][Full Text] [Related]
15. 5-HT(1A) and 5-HT(7) receptors differently modulate AMPA receptor-mediated hippocampal synaptic transmission.
Costa L; Trovato C; Musumeci SA; Catania MV; Ciranna L
Hippocampus; 2012 Apr; 22(4):790-801. PubMed ID: 21538661
[TBL] [Abstract][Full Text] [Related]
16. Extending therapeutic use of psychostimulants: focus on serotonin-1A receptor.
Haleem DJ
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():170-80. PubMed ID: 23906987
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist.
Picard M; Morisset S; Cloix JF; Bizot JC; Guerin M; Beneteau V; Guillaumet G; Hevor TK
Neuroscience; 2010 Sep; 169(3):1337-46. PubMed ID: 20580787
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.
Pettersson M; Campbell BM; Dounay AB; Gray DL; Xie L; O'Donnell CJ; Stratman NC; Zoski K; Drummond E; Bora G; Probert A; Whisman T
Bioorg Med Chem Lett; 2011 Jan; 21(2):865-8. PubMed ID: 21185183
[TBL] [Abstract][Full Text] [Related]
19. 5-HT(1A) receptors direct the orientation of plasticity in layer 5 pyramidal neurons of the mouse prefrontal cortex.
Meunier CN; Amar M; Lanfumey L; Hamon M; Fossier P
Neuropharmacology; 2013 Aug; 71():37-45. PubMed ID: 23523560
[TBL] [Abstract][Full Text] [Related]
20. Bidirectional modulation of classical fear conditioning in mice by 5-HT(1A) receptor ligands with contrasting intrinsic activities.
Youn J; Misane I; Eriksson TM; Millan MJ; Ogren SO; Verhage M; Stiedl O
Neuropharmacology; 2009; 57(5-6):567-76. PubMed ID: 19607850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
